MannKind Corporation (MNKD) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 19 analysts115.7% Below Target
MNKD trades 115.7% below Wall Street's consensus target of $8.50.
Current Price$3.94
Average Target$8.50
Target
Current
Low$6.00
Median$8.50
High$11.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth+77.4%
(High Growth)
Analyst Spread58.8%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes MNKD achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 19 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
MNKD Price Target Analysis
Updated June 22, 2026As of June 22, 2026, MannKind Corporation (MNKD) has a Wall Street consensus price target of $8.50, based on estimates from 19 covering analysts. With the stock currently trading at $3.94, this represents a potential upside of +115.7%. The company has a market capitalization of $1.22B.
Analyst price targets range from a low of $6.00 to a high of $11.00, representing a 59% spread in expectations. The median target of $8.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 7 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, MNKD trades at a trailing P/E of 197.0x. Analysts expect EPS to grow +77.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+39.4%
Industry Consensus
Avg Forward P/E
32.0x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 UTHRUnited Therapeutics Corporation | $22.8B | $536.59 | $636.83 | +18.7% | Buy | 18.9x | 30 |
 INSMInsmed Incorporated | $20.8B | $95.80 | $204.42 | +113.4% | Buy | — | 35 |
 ACADACADIA Pharmaceuticals Inc. | $3.7B | $21.62 | $33.67 | +55.7% | Buy | 55.6x | 37 |
 PTCTPTC Therapeutics, Inc. | $6.6B | $78.98 | $95.83 | +21.3% | Buy | 89.1x | 26 |
 RAREUltragenyx Pharmaceutical Inc. | $2.7B | $27.44 | $48.36 | +76.2% | Buy | — | 33 |
 NVONovo Nordisk A/S | $191.9B | $43.19 | $45.00 | +4.2% | Buy | 2.0x | 39 |
 SNYSanofi | $102.4B | $42.38 | $51.00 | +20.3% | Buy | 10.1x | 27 |
 LLYEli Lilly and Company | $1.0T | $1098.13 | $1271.24 | +15.8% | Buy | 30.0x | 45 |
 DXCMDexCom, Inc. | $28.0B | $72.47 | $83.56 | +15.3% | Buy | 28.0x | 52 |
 PODDInsulet Corporation | $10.2B | $145.76 | $223.15 | +53.1% | Buy | 22.5x | 50 |
MNKD — Frequently Asked Questions
Quick answers to the most common questions about buying MNKD stock.
What is the MNKD stock price target for 2026?
The consensus Wall Street price target for MNKD is $8.5, representing 115.7% upside from the current price of $3.94. With 19 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is MNKD a buy, sell, or hold?
MNKD has a consensus rating of "Buy" based on 19 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $8.5 implies 115.7% upside from current levels.
Is MNKD stock overvalued or undervalued?
MNKD's current price is $3.94 with a consensus target of $8.5 (115.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can MNKD stock go?
The most bullish Wall Street analyst has a price target of $11 for MNKD, while the most conservative target is $6. The consensus of $8.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover MNKD stock?
MNKD is well covered by analysts, with 19 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 3 recommend Hold, and 7 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the MNKD stock forecast?
The 12-month MNKD stock forecast based on 19 Wall Street analysts shows a consensus price target of $8.5, with estimates ranging from $6 (bear case) to $11 (bull case). The median consensus rating is "Buy".
Should I buy MNKD stock?
Wall Street analysts are very optimistic on MNKD, with a "Buy" consensus rating and $8.5 price target (115.7% upside). 9 of 19 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do MNKD price targets vary so much?
MNKD analyst price targets range from $6 to $11, a 59% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8.5 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare